New drug safety check for rare bile duct cancer
NCT ID NCT06793709
First seen Feb 28, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This study looks at the safety of the drug Tasfygo in 60 people with advanced biliary tract cancer that has a specific gene change (FGFR2 fusion) and has gotten worse after chemotherapy. Researchers will track side effects and how well the drug works. The goal is to make sure Tasfygo is safe for this group of patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
#Eisai Trial Site 1
RECRUITINGTokyo, Japan
Conditions
Explore the condition pages connected to this study.